{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,22]],"date-time":"2026-09-22T01:55:04Z","timestamp":1790042104977,"version":"4.0.1"},"reference-count":51,"publisher":"Impact Journals, LLC","issue":"42","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Oncotarget"],"published-print":{"date-parts":[[2015,12,29]]},"DOI":"10.18632\/oncotarget.6536","type":"journal-article","created":{"date-parts":[[2015,12,10]],"date-time":"2015-12-10T03:06:56Z","timestamp":1449716816000},"page":"44123-44133","source":"Crossref","is-referenced-by-count":51,"title":["Transpresentation of interleukin-15 by IL-15\/IL-15R\u03b1 mRNA-engineered human dendritic cells boosts antitumoral natural killer cell activity"],"prefix":"10.18632","volume":"6","author":[{"given":"Johan","family":"Van den Bergh","sequence":"first","affiliation":[{"name":"Laboratory of Experimental Hematology, Vaccine and Infectious Disease Institute (VAXINFECTIO), Faculty of Medicine and Health Sciences, University of Antwerp, Antwerp, Belgium"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yannick","family":"Willemen","sequence":"additional","affiliation":[{"name":"Laboratory of Experimental Hematology, Vaccine and Infectious Disease Institute (VAXINFECTIO), Faculty of Medicine and Health Sciences, University of Antwerp, Antwerp, Belgium"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eva","family":"Lion","sequence":"additional","affiliation":[{"name":"Laboratory of Experimental Hematology, Vaccine and Infectious Disease Institute (VAXINFECTIO), Faculty of Medicine and Health Sciences, University of Antwerp, Antwerp, Belgium"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Heleen","family":"Van Acker","sequence":"additional","affiliation":[{"name":"Laboratory of Experimental Hematology, Vaccine and Infectious Disease Institute (VAXINFECTIO), Faculty of Medicine and Health Sciences, University of Antwerp, Antwerp, Belgium"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hans","family":"De Reu","sequence":"additional","affiliation":[{"name":"Laboratory of Experimental Hematology, Vaccine and Infectious Disease Institute (VAXINFECTIO), Faculty of Medicine and Health Sciences, University of Antwerp, Antwerp, Belgium"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S\u00e9bastien","family":"Anguille","sequence":"additional","affiliation":[{"name":"Laboratory of Experimental Hematology, Vaccine and Infectious Disease Institute (VAXINFECTIO), Faculty of Medicine and Health Sciences, University of Antwerp, Antwerp, Belgium"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Herman","family":"Goossens","sequence":"additional","affiliation":[{"name":"Laboratory of Medical Microbiology, Vaccine and Infectious Disease Institute (VAXINFECTIO), Faculty of Medicine and Health Sciences, University of Antwerp, Antwerp, Belgium"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zwi","family":"Berneman","sequence":"additional","affiliation":[{"name":"Laboratory of Experimental Hematology, Vaccine and Infectious Disease Institute (VAXINFECTIO), Faculty of Medicine and Health Sciences, University of Antwerp, Antwerp, Belgium"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Viggo","family":"Van Tendeloo","sequence":"additional","affiliation":[{"name":"Laboratory of Experimental Hematology, Vaccine and Infectious Disease Institute (VAXINFECTIO), Faculty of Medicine and Health Sciences, University of Antwerp, Antwerp, Belgium"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Evelien","family":"Smits","sequence":"additional","affiliation":[{"name":"Laboratory of Experimental Hematology, Vaccine and Infectious Disease Institute (VAXINFECTIO), Faculty of Medicine and Health Sciences, University of Antwerp, Antwerp, Belgium"},{"name":"Center for Oncological Research Antwerp, Faculty of Medicine and Health Sciences, University of Antwerp, Antwerp, Belgium"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"7892","published-online":{"date-parts":[[2015,12,9]]},"reference":[{"key":"1","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1016\/j.smim.2010.05.001","article-title":"Cancer vaccines: the state of the art","volume":"22","author":"Banchereau","year":"2010","journal-title":"Semin Immunol"},{"key":"2","doi-asserted-by":"crossref","first-page":"13824","DOI":"10.1073\/pnas.1008051107","article-title":"Induction of complete and molecular remissions in acute myeloid leukemia by Wilms' tumor 1 antigen-targeted dendritic cell vaccination","volume":"107","author":"Schroyens","year":"2010","journal-title":"Proc Natl Acad Sci U S A"},{"key":"3","doi-asserted-by":"crossref","first-page":"1325","DOI":"10.4049\/jimmunol.0902539","article-title":"Recent developments in cancer vaccines","volume":"186","author":"Banchereau","year":"2011","journal-title":"J Immunol"},{"key":"4","doi-asserted-by":"crossref","first-page":"e51851","DOI":"10.1371\/journal.pone.0051851","article-title":"Interleukin-15-induced CD56(+) myeloid dendritic cells combine potent tumor antigen presentation with direct tumoricidal potential","volume":"7","author":"Berneman","year":"2012","journal-title":"PLoS One"},{"key":"5","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1016\/j.ejcb.2011.01.012","article-title":"Third generation dendritic cell vaccines for tumor immunotherapy","volume":"91","author":"Schendel","year":"2012","journal-title":"Eur J Cell Biol"},{"key":"6","doi-asserted-by":"crossref","first-page":"1093","DOI":"10.1007\/s00262-014-1600-5","article-title":"New generation dendritic cell vaccine for immunotherapy of acute myeloid leukemia","volume":"63","author":"Bigalke","year":"2014","journal-title":"Cancer Immunol Immunother"},{"key":"7","doi-asserted-by":"crossref","first-page":"1095","DOI":"10.1158\/1078-0432.CCR-13-2302","article-title":"Natural killer cells: the secret weapon in dendritic cell vaccination strategies","volume":"20","author":"Vanderlocht","year":"2014","journal-title":"Clin Cancer Res"},{"key":"8","first-page":"13","article-title":"Natural killer cells as helper cells in dendritic cell cancer vaccines","volume":"6","author":"Levy","year":"2015","journal-title":"Front Immunol"},{"key":"9","doi-asserted-by":"crossref","first-page":"2514","DOI":"10.4049\/jimmunol.1202797","article-title":"NK cells are required for dendritic cell-based immunotherapy at the time of tumor challenge","volume":"192","author":"McLellan","year":"2014","journal-title":"J Immunol"},{"key":"10","doi-asserted-by":"crossref","first-page":"1256","DOI":"10.1634\/theoncologist.2011-0122","article-title":"NK cells: key to success of DC-based cancer vaccines?","volume":"17","author":"Van Tendeloo","year":"2012","journal-title":"Oncologist"},{"key":"11","doi-asserted-by":"crossref","first-page":"e28582","DOI":"10.4161\/onci.28582","article-title":"A critical role for natural killer cells in dendritic cell-based anticancer immunotherapy","volume":"3","author":"McLellan","year":"2014","journal-title":"Oncoimmunology"},{"key":"12","doi-asserted-by":"crossref","first-page":"957","DOI":"10.2217\/imt.12.92","article-title":"Immunotherapeutic applications of IL-15","volume":"4","author":"Ferrini","year":"2012","journal-title":"Immunotherapy"},{"key":"13","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1016\/j.cytogfr.2011.04.001","article-title":"Interleukin 15 as a promising candidate for tumor immunotherapy","volume":"22","author":"Lasek","year":"2011","journal-title":"Cytokine Growth Factor Rev"},{"key":"14","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1016\/j.tips.2011.09.004","article-title":"Interleukin-15 biology and its therapeutic implications in cancer","volume":"33","author":"Morris","year":"2012","journal-title":"Trends Pharmacol Sci"},{"key":"15","doi-asserted-by":"crossref","first-page":"825","DOI":"10.1084\/jem.20041389","article-title":"Coordinate expression and trans presentation of interleukin (IL)-15Ralpha and IL-15 supports natural killer cell and memory CD8+ T cell homeostasis","volume":"200","author":"Ma","year":"2004","journal-title":"J Exp Med"},{"key":"16","doi-asserted-by":"crossref","first-page":"721","DOI":"10.1182\/blood-2003-12-4187","article-title":"Role of trans-cellular IL-15 presentation in the activation of NK cell-mediated killing, which leads to enhanced tumor immunosurveillance","volume":"105","author":"Tagaya","year":"2005","journal-title":"Blood"},{"key":"17","doi-asserted-by":"crossref","first-page":"1567","DOI":"10.1016\/j.biocel.2005.02.017","article-title":"The roles of interleukin-15 receptor alpha: trans-presentation, receptor component, or both?","volume":"37","author":"Lefrancois","year":"2005","journal-title":"Int J Biochem Cell Biol"},{"key":"18","doi-asserted-by":"crossref","first-page":"429","DOI":"10.1016\/S1359-6101(02)00029-1","article-title":"Regulation of lymphoid homeostasis by interleukin-15","volume":"13","author":"Ma","year":"2002","journal-title":"Cytokine Growth Factor Rev"},{"key":"19","doi-asserted-by":"crossref","first-page":"9166","DOI":"10.1073\/pnas.0600240103","article-title":"Converting IL-15 to a superagonist by binding to soluble IL-15R{alpha}","volume":"103","author":"Sprent","year":"2006","journal-title":"Proc Natl Acad Sci U S A"},{"key":"20","doi-asserted-by":"crossref","first-page":"6072","DOI":"10.4049\/jimmunol.177.9.6072","article-title":"Combined IL-15\/IL-15Ralpha immunotherapy maximizes IL-15 activity","volume":"177","author":"Lefrancois","year":"2006","journal-title":"J Immunol"},{"key":"21","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1016\/j.cytogfr.2014.09.001","article-title":"Interleukin-15: new kid on the block for antitumor combination therapy","volume":"26","author":"Smits","year":"2015","journal-title":"Cytokine Growth Factor Rev"},{"key":"22","doi-asserted-by":"crossref","first-page":"357","DOI":"10.1111\/j.1600-065X.2008.00604.x","article-title":"Twelve immunotherapy drugs that could cure cancers","volume":"222","author":"Cheever","year":"2008","journal-title":"Immunol Rev"},{"key":"23","doi-asserted-by":"crossref","first-page":"2417","DOI":"10.1182\/blood-2008-12-189266","article-title":"Safety and immunologic effects of IL-15 administration in nonhuman primates","volume":"114","author":"Riddell","year":"2009","journal-title":"Blood"},{"key":"24","doi-asserted-by":"crossref","first-page":"4787","DOI":"10.1182\/blood-2010-10-311456","article-title":"Safety (toxicity), pharmacokinetics, immunogenicity, and impact on elements of the normal immune system of recombinant human IL-15 in rhesus macaques","volume":"117","author":"Kurlander","year":"2011","journal-title":"Blood"},{"key":"25","article-title":"First-in-Humans Study of New Immunotherapy Agent","author":"Waldmann","year":"2012","journal-title":"NCI Cancer Bulletin"},{"key":"26","first-page":"423","article-title":"mRNA-based gene transfer as a tool for gene and cell therapy","volume":"9","author":"Berneman","year":"2007","journal-title":"Curr Opin Mol Ther"},{"key":"27","doi-asserted-by":"crossref","first-page":"4189","DOI":"10.1074\/jbc.M705725200","article-title":"Intracellular interaction of interleukin-15 with its receptor alpha during production leads to mutual stabilization and increased bioactivity","volume":"283","author":"Pavlakis","year":"2008","journal-title":"J Biol Chem"},{"key":"28","doi-asserted-by":"crossref","first-page":"2099","DOI":"10.4049\/jimmunol.180.4.2099","article-title":"Preassociation of IL-15 with IL-15R alpha-IgG1-Fc enhances its activity on proliferation of NK and CD8+\/CD44high T cells and its antitumor action","volume":"180","author":"Muller","year":"2008","journal-title":"J Immunol"},{"key":"29","doi-asserted-by":"crossref","first-page":"1072","DOI":"10.1158\/0008-5472.CAN-09-1301","article-title":"Interleukin-15 and its receptor augment dendritic cell vaccination against the neu oncogene through the induction of antibodies partially independent of CD4 help","volume":"70","author":"Morris","year":"2010","journal-title":"Cancer Res"},{"key":"30","doi-asserted-by":"crossref","first-page":"4851","DOI":"10.1128\/MCB.02178-07","article-title":"How a cytokine is chaperoned through the secretory pathway by complexing with its own receptor: lessons from interleukin-15 (IL-15)\/IL-15 receptor alpha","volume":"28","author":"Bulfone-Paus","year":"2008","journal-title":"Mol Cell Biol"},{"key":"31","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1177\/039463201002300104","article-title":"Increased tumor-specific CD8+ T cell induction by dendritic cells matured with a clinical grade TLR-agonist in combination with IFN-gamma","volume":"23","author":"Germeraad","year":"2010","journal-title":"Int J Immunopathol Pharmacol"},{"key":"32","doi-asserted-by":"crossref","first-page":"503","DOI":"10.1016\/j.immuni.2007.03.006","article-title":"Dendritic cells prime natural killer cells by trans-presenting interleukin 15","volume":"26","author":"Diefenbach","year":"2007","journal-title":"Immunity"},{"key":"33","doi-asserted-by":"crossref","first-page":"4948","DOI":"10.4049\/jimmunol.0900719","article-title":"Dendritic cells support thedevelopment and maintenance of NK cells via IL-15 trans-presentation","volume":"183","author":"Schluns","year":"2009","journal-title":"J Immunol"},{"key":"34","doi-asserted-by":"crossref","first-page":"575","DOI":"10.1182\/blood-2009-08-240325","article-title":"Virally infected and matured human dendritic cells activate natural killer cells via cooperative activity of plasma membrane-bound TNF and IL-15","volume":"116","author":"Butterfield","year":"2010","journal-title":"Blood"},{"key":"35","doi-asserted-by":"crossref","first-page":"2497","DOI":"10.1158\/0008-5472.CAN-10-3025","article-title":"IL-15 and type I interferon are required for activation of tumoricidal NK cells by virus-infected dendritic cells","volume":"71","author":"Wan","year":"2011","journal-title":"Cancer Res"},{"key":"36","doi-asserted-by":"crossref","first-page":"1956","DOI":"10.4161\/hv.25373","article-title":"Interleukin-15 dendritic cells as vaccine candidates for cancer immunotherapy","volume":"9","author":"Berneman","year":"2013","journal-title":"Hum Vaccin Immunother"},{"key":"37","doi-asserted-by":"crossref","first-page":"e959321","DOI":"10.4161\/21624011.2014.959321","article-title":"Dendritic cell-derived interleukin-15 is crucial for therapeutic cancer vaccine potency","volume":"3","author":"You","year":"2014","journal-title":"Oncoimmunology"},{"key":"38","doi-asserted-by":"crossref","first-page":"e0123340","DOI":"10.1371\/journal.pone.0123340","article-title":"Interleukin-15 Dendritic Cells Harness NK Cell Cytotoxic Effector Function in a Contact- and IL-15-Dependent Manner","volume":"10","author":"Lion","year":"2015","journal-title":"PLoS One"},{"key":"39","doi-asserted-by":"crossref","first-page":"1213","DOI":"10.1084\/jem.20071913","article-title":"IL-15Ralpha chaperones IL-15 to stable dendritic cell membrane complexes that activate NK cells via trans presentation","volume":"205","author":"Ma","year":"2008","journal-title":"J Exp Med"},{"key":"40","doi-asserted-by":"crossref","first-page":"21647","DOI":"10.1073\/pnas.1012128107","article-title":"Mature natural killer cells with phenotypic and functional alterations accumulate upon sustained stimulation with IL-15\/IL-15Ralpha complexes","volume":"107","author":"Turley","year":"2010","journal-title":"Proc Natl Acad Sci U S A"},{"key":"41","doi-asserted-by":"crossref","first-page":"579","DOI":"10.4161\/hv.7.5.14652","article-title":"Dendritic cell vaccine therapy for acute myeloid leukemia: questions and answers","volume":"7","author":"van Tendeloo","year":"2011","journal-title":"Hum Vaccin"},{"key":"42","doi-asserted-by":"crossref","first-page":"e20952","DOI":"10.1371\/journal.pone.0020952","article-title":"Poly(I:C) enhances the susceptibility of leukemic cells to NK cell cytotoxicity and phagocytosis by DC","volume":"6","author":"Van Tendeloo","year":"2011","journal-title":"PLoS One"},{"key":"43","doi-asserted-by":"crossref","first-page":"647","DOI":"10.3109\/14653249.2012.693744","article-title":"Dendritic cell vaccination in acute myeloid leukemia","volume":"14","author":"Berneman","year":"2012","journal-title":"Cytotherapy"},{"key":"44","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1053\/j.seminhematol.2015.03.006","article-title":"Immunotherapy for Acute Myeloid Leukemia","volume":"52","author":"Subklewe","year":"2015","journal-title":"Semin Hematol"},{"key":"45","doi-asserted-by":"crossref","first-page":"234","DOI":"10.1182\/asheducation-2013.1.234","article-title":"Bringing natural killer cells to the clinic:manipulation","volume":"2013","author":"Berg","year":"2013","journal-title":"Hematology Am Soc Hematol Educ Program"},{"key":"46","doi-asserted-by":"crossref","first-page":"2353","DOI":"10.4049\/jimmunol.1500300","article-title":"IL-15 Superagonist-Mediated Immunotoxicity: Role of NK Cells and IFN-gamma","volume":"195","author":"Sherwood","year":"2015","journal-title":"J Immunol"},{"key":"47","first-page":"3877","article-title":"Interleukin 15 promotes antigen-independentexpansion and long-term survival of antitumor cytotoxic T lymphocytes","volume":"8","author":"Celis","year":"2002","journal-title":"Clin Cancer Res"},{"key":"48","doi-asserted-by":"crossref","first-page":"112","DOI":"10.4049\/jimmunol.175.1.112","article-title":"Coimmunization with an optimized IL-15 plasmid results in enhanced function and longevity of CD8 T cells that are partially independent of CD4 T cell help","volume":"175","author":"Kim","year":"2005","journal-title":"J Immunol"},{"key":"49","doi-asserted-by":"crossref","first-page":"4009","DOI":"10.1182\/blood-2006-04-015024","article-title":"Modification of antigen-encoding RNA increases stability, translational efficacy, and T-cell stimulatory capacity of dendritic cells","volume":"108","author":"Sahin","year":"2006","journal-title":"Blood"},{"key":"50","doi-asserted-by":"crossref","first-page":"831","DOI":"10.1007\/s00262-015-1688-2","article-title":"Engineering monocyte-derived dendritic cells to secrete interferon-alpha enhances their ability to promote adaptive and innate anti-tumor immune effector functions","volume":"64","author":"Adema","year":"2015","journal-title":"Cancer Immunol Immunother"},{"key":"51","doi-asserted-by":"crossref","first-page":"1372","DOI":"10.1111\/jcmm.12284","article-title":"HPV vaccine stimulates cytotoxic activity of killer dendritic cells and natural killer cells against HPV-positive tumour cells","volume":"18","author":"Smits","year":"2014","journal-title":"J Cell Mol Med"}],"container-title":["Oncotarget"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.oncotarget.com\/lookup\/doi\/10.18632\/oncotarget.6536","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,5,13]],"date-time":"2020-05-13T18:41:06Z","timestamp":1589395266000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.oncotarget.com\/lookup\/doi\/10.18632\/oncotarget.6536"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2015,12,9]]},"references-count":51,"journal-issue":{"issue":"42","published-print":{"date-parts":[[2015,12,29]]}},"alternative-id":["6536","26675759"],"URL":"https:\/\/doi.org\/10.18632\/oncotarget.6536","relation":{},"ISSN":["1949-2553"],"issn-type":[{"value":"1949-2553","type":"electronic"}],"subject":[],"published":{"date-parts":[[2015,12,9]]}}}